Blog - Pharmaceutical Preparation

Vertex Pharmaceuticals Sees Promising Growth with CF Treatments and New Pain Drug

Feb 10, 2025

Vertex Pharmaceuticals projects a notable revenue increase by leveraging its cystic fibrosis treatments and new pain management medication, Journavx, with plans for future growth.

Merck KGaA Eyes Major Acquisition in Oncology Sector

Feb 10, 2025

202

Merck KGaA is in advanced talks to acquire Springworks Therapeutics, aiming to enhance its oncology portfolio amid renewed healthcare transaction activity.

Incyte Corporation Set to Announce Quarterly Earnings

Feb 9, 2025

542

Discover Incyte Corporation's projected quarterly earnings with a 12.9% revenue growth, aligned with industry trends and analyst forecasts.

Bristol Myers Squibb Predicts Revenue Drop by 2025 Due to Generic Drugs

Feb 6, 2025

Bristol Myers Squibb faces upcoming revenue challenges by 2025 due to generic competition and patent losses, impacting its financial outlook.

Bain Capital Approaches Acquisition of Mitsubishi's Pharma Arm

Feb 6, 2025

164

Bain Capital is on the verge of acquiring Mitsubishi Chemical's pharmaceutical division, valued at $3.3 billion, marking a significant step in Japan's pharmaceutical sector.

Pfizer Surpasses Earnings Expectations for Q4 and FY 2024

Feb 4, 2025

110

Pfizer surpasses Q4 and FY 2024 earnings expectations, with a strategic focus on cost reductions and revenue growth, overcoming challenges such as patent expirations and Medicare negotiations.

Regeneron Pharmaceuticals Surpasses Quarterly Expectations and Announces Financial Initiatives

Feb 4, 2025

Regeneron Pharmaceuticals exceeds expectations with strong Dupixent sales, proposes dividend and share repurchase, maintaining a competitive edge despite challenges.

Eli Lilly Prepares for Strong Earnings Report Amid High Analyst Expectations

Feb 3, 2025

120

Pharmaceutical giant Eli Lilly is poised for an impressive earnings report, powered by strong sales of its weight-loss drugs and a strategic market approach.

AbbVie Projects Surpassing 2025 Profit Expectations with Immunology Drug Surge

Jan 31, 2025

140

AbbVie predicts exceeding 2025 profit expectations, bolstered by immunology drugs Skyrizi and Rinvoq, as Humira faces declining sales and rising competition.

Metsera and Maze Therapeutics Lead Record Month for US Health Care IPOs

Jan 31, 2025

152

Metsera Inc. and Maze Therapeutics Inc. contribute to the most prolific month for US healthcare IPOs, raising over $750 million.

Pharmaceutical Price Hikes Surge Amid Economic Challenges

Jan 28, 2025

112

Explore the reasons behind the surge in prescription drug prices in 2023, how it compares to previous years, and its impact on the healthcare industry.

Akero Therapeutics' Shares Skyrocket on Promising Liver Disease Treatment Results

Jan 27, 2025

211

Akero Therapeutics experienced a share surge after announcing promising results for its liver disease treatment, EFX, in reversing cirrhosis symptoms without worsening MASH.